Jones Financial Companies
TSHA icon

Jones Financial Companies’s Taysha Gene Therapies TSHA Stock Holding History

Jones Financial Companies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.26K Buy
1,461
+900
+160% +$5.33K ﹤0.01% 3828
2026
Q1 		$2.28K Buy
+561
New +$2.61K ﹤0.01% 4114

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jones Financial Companies's TSHA Position: Q2 2026 in Review

Jones Financial Companies increased its Taysha Gene Therapies (TSHA) stake by 160% in Q2 2026, buying an estimated $5.33K and bringing the position to 1,461 shares worth $9.26K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

Jones Financial Companies first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Jones Financial Companies held 1,461 shares of Taysha Gene Therapies worth $9.26K as of Q2 2026.
  • Jones Financial Companies bought 900 Taysha Gene Therapies shares in Q2 2026, an estimated $5.33K.
  • Taysha Gene Therapies made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3828 holding.
  • Jones Financial Companies first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.